A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

NCT00064259 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

15

Enrollment

NIH

Sponsor class

Stopped Discontinued development of G3139 (oblimersen)

Conditions

Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Diffuse Adenocarcinoma of the Stomach
Intestinal Adenocarcinoma of the Stomach
Mixed Adenocarcinoma of the Stomach
Recurrent Esophageal Cancer
Recurrent Gastric Cancer
Squamous Cell Carcinoma of the Esophagus
Stage III Esophageal Cancer
Stage IIIA Gastric Cancer
Stage IIIB Gastric Cancer
Stage IIIC Gastric Cancer
Stage IV Esophageal Cancer
Stage IV Gastric Cancer

Interventions

BIOLOGICAL: oblimersen sodium
DRUG: cisplatin
DRUG: fluorouracil

Sponsor

National Cancer Institute (NCI)